Objective: An increased cardiovascular mortality and morbidity has been widely reported in patients with atrial fibrillation (AF). In this study, a subanalysis of the AntiThrombotic Agents Atrial Fibrillation (ATA-AF) is performed with the aim to evaluate estimated glomerular filtration rate (eGFR) as an independent prognostic marker of cardiovascular mortality and morbidity in patients with AF.
In contrast, chronic kidney disease (CKD), which had been not included in the algorithm for thromboembolic risk stratification in patients with AF, is a well-known risk factor for mortality, cardiovascular events, and hospitalization in the general population. [4] [5] [6] In large population from the Danish national registry, Olesen et al 7 reported that CKD is independently associated with stroke and systemic embolism in patients with AF.
More recently, an impaired glomerular filtration rate (GFR) combined with a high CHADS score has been shown to be an effective predictor of cardiovascular event and mortality in patients with AF. 8 The AntiThrombotic Agents Atrial Fibrillation (ATA-AF) study 9 is a multicenter observational study that assessed the differences in clinical profile and treatment strategies between patients with AF, referred to cardiology and internal medicine units.
A subanalysis on the ATA-AF population is presented with the aim to evaluate the association between estimated glomerular filtration rate (eGFR) and cardiovascular mortality and morbidity in patients with AF.
| METHODS
The ATA-AF study has been described somewhere else 9 ; briefly from May to July 2010, 7148 patients with AF, of which 4845 with a nonvalvular form, were enrolled in 360 Italian centers. A substudy was run in 64 centers that followed-up a total of 1368 patients for 1 year; among these 1097 patients had data on eGFR and were included in this subanalysis. The clinical and therapeutic management was assessed according to the department of admission, either medicine or cardiology. The only exclusion criterion was AF after acute coronary syndrome or cardiothoracic surgery (within 1 week from symptom onset or surgery).
Information regarding occurrence of major cardiovascular events requiring hospitalization or mortality were collected at follow-up visits or through phone calls to the patients and their relatives.
All patients gave written informed consent. The study protocol conforms to the ethical guidelines of the Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. The eGFR was calculated from data reported in patient notes or hospital database, according to the CKD-EPI Creatinine Equation.
The clinical outcome was assessed as composite endpoint of cardiovascular mortality and/or hospital admission for cardiovascular causes at 1-year follow-up. Occurrence of thromboembolic events, including ischemic and hemorrhagic stroke, pulmonary, or peripheral embolism, was assessed as a secondary endpoint.
In our analysis, an eGFR of 60 mL/min/1.73 m 2 , was used as cutoff point to assign patients into two groups; equal and above (preserved eGFR), or below the cutoff point (impaired eGFR). In order to evaluate the effect of eGFR on the clinical outcome we also considered eGFR both as a continuous variable and in three groups <30 mL/min/1.73 m 2 , from 30 to 59 mL/min/1.73 m 2 , and ≥60 mL/min/1.73 m 2 .
| Statistical analysis
Continuous variable are expressed as mean and SDs, and were compared by Mann-Whitney U test. Categorical variables are reported as number and percentages, and were compared by χ 2 test. A multivariable analysis (Cox regression) was used to determine the independent predictors of the combined endpoint of cardiovascular mortality and/or hospitalization for cardiovascular causes at 1 year follow-up, using the variables that were statistically significant at univariate analysis (eGFR among these), and gender and age, even though not significant. Three models were performed, the first with eGFR in two classes (<60;
≥60 mL/min/1.73 m 2 ), the second with eGFR in three classes (<30; 30-59; ≥60 mL/min/1.73 m 2 , with the latter as reference group), and the last with eGFR as continuous. Kaplan-Meier curves for the combined outcome were produced by eGFR (preserved vs impaired), and compared by log-rank test. For the eGFR the linearity of the risk was evaluated by restricted cubic splines. A P value <0.05 was considered statistically significant. All analyses were performed with SAS system software (SAS Institute Inc, Cary, NC, USA), version 9.2.
| RESULTS

| Baseline characteristics
In the ATA-AF study population, data on GFR were available in 5681 of 7148 enrolled patients (79.5%). Baseline clinical characteristics of patients with and without data on eGFR are shown in Supporting Information Table S1 . Patients with data on GFR were older and had a higher CHADS 2 score and a lower body mass index (BMI). Table S2 . Patients with an eGFR and 1-year clinical follow-up were younger, more likely to be admitted in a cardiology department, and had a lower CHADS 2 and CHA 2 D 2 SVasc score. Prevalence of cognitive deficit and dementia, stroke, peripheral vascular disease, cancer, anemia, and chronic obstructive pulmonary disease (COPD) was significantly lower among patients with eGFR and clinical follow-up. Persistent AF was more prevalent among patients with follow-up while paroxysmal and permanent AF were more prevalent among patients without. Finally, patients with clinical follow-up were more likely to be on oral anticoagulants (OAC) and propafenone, and less on ASA.
Among the 1097 patients with eGFR and 1-year follow-up data, 459 (42%) had eGFR <60 mL/min/1.73 m 2 , while 638 (58%) had eGFR ≥60 mL/min/1.73 m 2 . A comparison between the baseline characteristics of patients with 1-year follow-up divided in the two groups according to eGFR is reported in Table 1 . Patients with an eGFR <60 mL/min/1.73 m 2 were older, less likely to be admitted in a cardiology department, predominantly female and not smokers, and had a higher CHADS 2 and CHA 2 D 2 SVasc score. In this subgroup, the prevalence of cognitive deficit, heart failure, hypertension, diabetes and TIA, peripheral vascular disease, cancer, anemia, and COPD was significantly higher. observed in the group with eGFR below 60 (χ 2 = 9.8, P = 0.002) ( Table 2) .
| Clinical outcome
Accordingly, the Kaplan-Meyer curve for the composite endpoint of cardiovascular mortality and/or hospitalization for cardiovascular causes at 1-year follow-up showed a higher incidence of new events in the group of patients with eGFR below 60 mL/min/1.73 m 2 (Pvalue long-rank <0.001) ( Figure 1 ). 
| Model with eGFR as continuous variable
In the third analysis, the eGFR was considered as a continuous variable. Univariate Cox regression assessing the association between the composite endpoint (mortality/hospital admission for CV causes) and the eGFR showed a significant inverse correlation (HR 0.987, 95% CI 0.981-0.993, P < 0.0001). In the adjusted analysis that included the other clinical variables the association between level of eGFR and clinical endpoints was also statistically significant (HR 0.99, 95% CI 0.98-0.99, P = 0.04) (Table 3C ).
| DISCUSSION
The results of our post-hoc analysis performed on the data of the ATA-AF study shows that eGFR is independently associated with worse prognosis in patients with AF. An impaired eGFR heralds a higher risk for cardiovascular morbidity and mortality among patients with AF.
The association between mortality and AF has recently become more apparent; three epidemiological studies [10] [11] [12] It has been clearly demonstrated that CKD and AF share the same pathophysiological mechanisms. 18 For instance, Watanabe et al 19 in a community-based prospective study including 231 818 subjects, reported a bidirectional risk between patients with CKD and AF. Specifically, the authors reported a 77% increase in the risk of developing CKD in patients with AF. Hence, it may be hypothesized that renal impairment can act in conferring poor prognosis in patients with AF as progressive eGFR deterioration that fails to be detected as dichotomous discriminator.
The bidirectional link between AF and renal function is further confirmed by studies conducted in patients who underwent catheter ablation; evidence from a recent meta-analysis showed a higher incidence of AF recurrence after catheter ablation in patients with CKD. 20 In addition, more recently, a decline of eGFR has been shown to be associated with episodes of AF recurrence after ablation. 21 An improvement in eGFR has been detected in patients with mild and moderate renal impairment who were free of arrhythmia recurrence after catheter ablation. 22 Conversely, patients with AF and normal renal function or mild renal dysfunctions treated medically experience a decline in eGFR that is associated with increased thromboembolic events and mortality. 23 In support of this finding, our results show a significant association between eGFR levels and the primary combined endpoint of the analysis.
Finally, our analysis detected a significantly higher incidence of thromboembolic events in patients with an impaired renal function.
This finding is in line with recent evidences that suggest impaired renal function as a potential predictor of thromboembolic events. 24 
| Limitations
The main limitation of this study is that it represents a post-hoc analysis of a study originally designed with a different aim. Furthermore, only a small subset of the ATA-AF population had data on eGFR and
1-year follow-up and could be included in the analysis. Finally, our results are limited at 1-year follow-up and do not provide long-term follow-up.
| CONCLUSION
The result of this post-hoc analysis indicates that an impaired eGFR is independently associated with a worse prognosis among patients with AF.
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